One of the kinases involved in the regulation of signal transduction pathways mediating resistance to therapies targeting BRAFV600E in melanoma is PKCα [38,39,86]; this suggests that a combination therapy targeting both proteins could yield better outcomes in TC patients carrying the BRAFV600E or NRAS mutation, overexpression of PKCα [38]. This evidence concerns the gene PRKCA and melanoma.